回 购 注 销 剩 余 全 部 限 制 性 股 票 实 施 情 况 的 关 于 江 苏 康 缘 药 业 股 份 有 限 公 司 江 苏 世 纪 同 仁 律 师 事 务 所 2022 年 度 限 制 性 股 票 激 励 计 划 法 律 意 见 书 苏 同 律 证 字 2025 第 [101]号 南 京 市 建 邺 区 贤 坤 路 江 岛 智 立 方 C 座 4 层 邮 编 ： 2 1 0 0 1 9 电 话 ： + 8 6 2 5 - 8 3 3 0 4 4 8 0 传 真 ： + 8 6 2 5 - 8 3 3 2 9 3 3 5 江苏世纪同仁律师事务所 法律意见书 江苏世纪同仁律师事务所关于 江苏康缘药业股份有限公司 2022 年度限制性股票激励计划 回购注销剩余全部限制性股票实施情况的 法 律 意 见 书 苏同律证字（2025）第[101]号 致：江苏康缘药业股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共 和国证券法》（以下简称"《证券法》"）《上海证券交易所股票上市规则》（以 下简称"上市规则"）《上市公司股权激励管理办法》（以下简称"《管理办法》"） 等有关法律、法规 ...

证券简称：康缘药业 证券代码：600557 公告编号：2025-020 江苏康缘药业股份有限公司 关于召开 2024 年度暨 2025 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ? 会议召开时间：2025 年 5 月 29 日（星期四）13:30-14:30 ? 会议召开地点：上证路演中心 http://roadshow.sseinfo.com ? 会议召开方式：上证路演中心网络互动 ? 投资者可于 5 月 27 日(星期二)16:00 前登录上证路演中心网站首页点击"提 问预征集"栏目进行提问，公司将在说明会上对投资者普遍关注的问题进行解答。 江苏康缘药业股份有限公司（以下简称"公司"）分别于 2025 年 4 月 3 日、 及上海证券交易所网站www.sse.com.cn披露了公司《2024 年年度报告》《2025 年第一季度报告》。为便于广大投资者更全面深入地了解公司 2024 年及 2025 年第一季度经营成果、财务状况，公司计划于 2025 年 5 月 29 ...

证券简称：康缘药业 证券代码：600557 公告编号：2025-020 江苏康缘药业股份有限公司 关于召开 2024 年度暨 2025 年第一季度 一、说明会类型 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可于 5 月 27 日(星期二)16:00 前登录上证路演中心网站首页点击"提 问预征集"栏目进行提问，公司将在说明会上对投资者普遍关注的问题进行解答。 江苏康缘药业股份有限公司（以下简称"公司"）分别于 2025 年 4 月 3 日、 2025 年 4 月 30 日在《上海证券报》《中国证券报》《证券日报》《证券时报》 及上海证券交易所网站www.sse.com.cn披露了公司《2024 年年度报告》《2025 年第一季度报告》。为便于广大投资者更全面深入地了解公司 2024 年及 2025 年第一季度经营成果、财务状况，公司计划于 2025 年 5 月 29 日（星期四） 13:30-14:30 举行 2024 年度暨 2025 年第一季度业绩说明会，就投资者关心的问 ...

Core Viewpoint - Kangyuan Pharmaceutical has signed two contracts totaling 258 million yuan with the same related party within a year, leading to the major shareholder, Jiangsu Kangyuan Group, choosing to exit the related party, Jiangsu Kunyue Construction Engineering Co., Ltd. [1] Group 1: Related Party Transactions - Jiangsu Kunyue was established in January 2023 and initially named Nantong Mingyuan Construction Engineering Co., Ltd. Kangyuan Group invested in it in September 2023 but exited two months later, transferring ownership to its wholly-owned subsidiary, Jiangsu Yuansen Real Estate Co., Ltd. [1] - In December 2023, Kangyuan Pharmaceutical announced a related transaction where its subsidiary, Jiangsu Kangyuan Pharmaceutical Technology Development Co., Ltd., signed a construction contract with Nantong Mingyuan for 94.4472 million yuan. [2] - Five months after the first transaction, Nantong Mingyuan was renamed Jiangsu Xinjiyu Construction Engineering Co., Ltd. and relocated to Jiangsu Province. [3] Group 2: Financial Impact and Regulatory Attention - In July 2024, Kangyuan Pharmaceutical announced another related transaction with Jiangsu Xinjiyu, with a total estimated contract value of 163 million yuan, bringing the total related transactions to 258 million yuan, which accounts for 4.96% of Kangyuan Pharmaceutical's audited net assets for 2023. [4] - The Shanghai Stock Exchange sent a regulatory letter to Kangyuan Pharmaceutical regarding these transactions, prompting the company to clarify its bidding process and confirm Jiangsu Xinjiyu as the winning bidder. [5] Group 3: Corporate Structure and Governance - After securing a new contract worth 163 million yuan, Jiangsu Xinjiyu was renamed Jiangsu Kunyue again in December 2024, with a new investor, Nanjing Yichen Investment Co., Ltd., acquiring a 67% stake. [6] - Kangyuan Pharmaceutical stated that Jiangsu Kunyue is no longer a related party as of December 12, 2024, following the transfer of shares. [6] - The company emphasized that it has adhered to legal and regulatory requirements regarding related transactions and will reassess Jiangsu Kunyue's status after the 12-month period. [6][9]

Core Viewpoint - The traditional Chinese medicine (TCM) industry is undergoing transformation, with a focus on quality stability and uniformity of traditional Chinese patent medicines, while 康缘药业 (Kangyuan Pharmaceutical) emphasizes intelligent manufacturing alongside research and innovation [2][3]. Group 1: Intelligent Manufacturing - 康缘药业 has transitioned from traditional to intelligent manufacturing, utilizing automated and digital production processes to enhance efficiency and control in TCM extraction [2]. - The company has implemented over 20 technological breakthroughs, including fully automated extraction workshops and AI-driven quality control systems, showcasing its unique competitive edge in the industry [2]. - 康缘药业's intelligent manufacturing team has established three key construction goals: data collection and governance, intelligent decision-making, and intelligent regulation, successfully overcoming four core technical challenges in online detection and quality modeling [3]. Group 2: Achievements and Recognition - 康缘药业 has designed and built China's first intelligent factory for TCM extraction and developed the first big data-driven TCM production process knowledge system (PKS), recognized as a national pilot demonstration for intelligent manufacturing [3]. - The company has received multiple honors, including being named an "Advanced Unit in Intelligent Manufacturing" in Jiangsu Province and recognized as an "Excellent Scene in Intelligent Manufacturing" at the national level [3]. Group 3: Compliance and Market Strategy - 康缘药业 balances intelligent manufacturing with compliance and academic promotion, establishing a product matrix and a compliance system to enhance market competitiveness [4]. - The company employs a "self-built sales team + academic promotion" model to gather real-time clinical feedback, creating a positive feedback loop that informs research and production [4]. - Despite facing challenges during its reform efforts, 康缘药业 remains committed to its foundational principles of research and intelligent manufacturing, aiming to innovate while preserving traditional Chinese medicine [4].

Core Viewpoint - The company has reported a significant decline in revenue and costs for its main products in the first quarter of 2025, primarily due to decreased sales of specific injection and oral liquid products [11]. Financial Data - The company completed the acquisition of 100% equity in Jiangsu Zhongxin Pharmaceutical Co., which is now a wholly-owned subsidiary and included in the financial statements [3]. - The company has not audited its first-quarter financial statements [10]. Non-Recurring Gains and Losses - The company has identified non-recurring gains and losses, but specific amounts and reasons are not detailed in the provided documents [4]. Shareholder Information - The company has implemented a share repurchase plan, extending the repurchase period by 9 months and increasing the maximum repurchase price from 18 RMB to 20 RMB per share [6]. - As of February 5, 2025, the company repurchased a total of 12,338,346 shares for approximately 185.91 million RMB [7]. - The controlling shareholder's action plan to increase holdings was completed, with 2,478,700 shares purchased for approximately 34.23 million RMB [8]. Product Development - The company has received clinical trial approval for several products, including solid granules and capsules for specific indications [8]. - The focus areas for Jiangsu Zhongxin Pharmaceutical include metabolic and neurological diseases, with multiple innovative drugs in various clinical trial phases [9].

证券简称：康缘药业 证券代码：600557 公告编号：2025-019 江苏康缘药业股份有限公司 关于 2025 年第一季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏康缘药业股份有限公司（以下简称"公司"）根据上海证券交易所发布 的《上海证券交易所上市公司自律监管指引第 3 号—行业信息披露》的相关要求， 现将公司 2025 年第一季度主要经营数据披露如下： 江苏康缘药业股份有限公司董事会 | | | | 毛利 | 营业收入 比上年同 | 营业成本 | 毛利率比上年同期增 | | --- | --- | --- | --- | --- | --- | --- | | 分地区 | 营业收入 | 营业成本 | | | 比上年同 | | | | | | 率（%） | 期增减 | 期增减（%） | 减（%） | | | | | | （%） | | | | 国内销售 | 867,216,343.48 | 222,677,030.89 | 74.32 | -35.79 | -34.35 | 减少 0.57 个 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 877,554,089.34, a decrease of 35.38% compared to CNY 1,359,020,285.93 in the same period last year[5] - Net profit attributable to shareholders was CNY 83,412,980.21, down 38.37% from CNY 148,044,958.72 year-on-year[5] - Basic earnings per share decreased by 34.78% to CNY 0.15 from CNY 0.23 in the previous year[6] - Total operating revenue for Q1 2025 was CNY 877,554,089.34, a decrease of 35.4% compared to CNY 1,358,009,437.31 in Q1 2024[27] - Net profit for Q1 2025 was CNY 85,552,385.18, a decline of 34.9% from CNY 131,428,235.70 in Q1 2024[28] - Basic and diluted earnings per share for Q1 2025 were CNY 0.15, compared to CNY 0.23 in Q1 2024[28] Cash Flow - The net cash flow from operating activities fell by 59.90% to CNY 76,936,099.28, compared to CNY 198,867,926.89 in the same period last year[5] - In Q1 2025, the cash inflow from operating activities was CNY 996,812,504.48, a decrease of 32.5% compared to CNY 1,476,632,797.58 in Q1 2024[30] - The net cash flow from operating activities for Q1 2025 was CNY 76,936,099.28, down 60.1% from CNY 191,883,451.67 in Q1 2024[30] - The cash flow from other operating activities decreased to CNY 43,558,462.11 in Q1 2025 from CNY 93,374,608.68 in Q1 2024, a decline of 53.3%[30] - The company experienced a net decrease in cash and cash equivalents of CNY 73,609,393.53 in Q1 2025, contrasting with an increase of CNY 66,900,832.33 in Q1 2024[31] Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,884,778,092.97, a slight decrease of 0.32% from CNY 6,906,762,381.38 at the end of the previous year[6] - Cash and cash equivalents as of March 31, 2025, were CNY 2,094,172,093.81, down from CNY 2,195,076,101.94 at the end of 2024[23] - Total liabilities as of March 31, 2025, were CNY 2,094,135,216.35, a decrease from CNY 2,201,671,889.94 at the end of 2024[25] - Inventory as of March 31, 2025, was CNY 515,373,930.80, down from CNY 540,269,821.74 at the end of 2024[23] Research and Development - The company reported a significant increase in prepayments by 32.49%, primarily due to increased R&D expenses[9] - The company’s major R&D projects include four innovative biological drugs, with clinical trials showing good safety, tolerability, and preliminary efficacy results[19] - The company’s major focus areas for R&D are metabolic diseases and neurological disorders, with multiple projects in various clinical trial phases[19] - Research and development expenses for Q1 2025 were CNY 131,914,970.39, a decrease from CNY 214,961,528.07 in Q1 2024[27] - The company received clinical trial approval for three new drug indications during the reporting period[18] Shareholder Activities - The top shareholder, Jiangsu Kangyuan Group Co., Ltd., holds 30.94% of the shares, totaling 176,173,467 shares[11] - The company repurchased a total of 12,338,346 shares, with a total payment of RMB 185,909,622.90, and all repurchased shares will be canceled[15] - The company plans to extend the share repurchase period by 9 months, from May 6, 2024, to February 5, 2025, and increase the maximum repurchase price from RMB 18 to RMB 20 per share[14] - The total amount allocated for the share repurchase plan is between RMB 1.5 billion and RMB 3 billion[14] - The company’s stock repurchase plan aims to maintain company value and protect shareholder interests[14] - The company’s controlling shareholder, Nanjing Kangzhu, completed a share increase plan, acquiring 2,478,700 shares for a total of RMB 34,228,626.33[17] - The top shareholder, Jiangsu Kangyuan Group, holds 176,173,467 shares, representing a significant portion of the company's equity[13] - The company has not reported any changes in the participation of major shareholders in margin financing or securities lending activities[13] Investment Activities - The company’s investment activities generated a net cash flow of -CNY 151 million, compared to -CNY 109 million in the previous year, indicating increased investment outflows[9] - The net cash flow from investing activities in Q1 2025 was -CNY 150,552,818.14, compared to -CNY 108,503,090.98 in Q1 2024, indicating a worsening investment cash flow situation[31] - The total cash inflow from investment activities in Q1 2025 was CNY 228,838,490.05, down 55.6% from CNY 514,816,096.34 in Q1 2024[31] - The cash outflow for investment activities in Q1 2025 was CNY 379,391,308.19, a decrease of 39.1% compared to CNY 623,319,187.32 in Q1 2024[31] - The company reported a cash outflow of CNY 16,479,528.36 from financing activities in Q1 2025, with no cash inflow recorded[31]

Group 1 - The core point of the article is that Kangyuan Pharmaceutical (600557) reported a significant decline in both revenue and net profit for the first quarter of 2025 compared to the same period last year [1] Group 2 - The company's revenue for Q1 2025 was 878 million yuan, representing a year-on-year decrease of 35.38% [1] - The net profit for the same period was 83.41 million yuan, showing a year-on-year decline of 38.37% [1]

江苏康缘药业股份有限公司 关于获得玉女煎颗粒药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏康缘药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管理 局签发的玉女煎颗粒《药品注册证书》。按照《上海证券交易所上市公司自律监管 指引第 3 号——行业信息披露》的相关要求，现将药品相关情况公告如下： 证券简称：康缘药业 证券代码：600557 公告编号：2025-018 注册分类：中药 3.1 类 是否独家：是 功能主治：清胃热，滋肾阴。用于胃热阴虚证。症见头痛，牙痛，齿松牙衄， 烦热干渴，或消渴，消谷善饥，舌红苔黄而干，脉浮洪或滑。 药品有效期：24 个月 处方药/非处方药：处方药 药品注册标准编号：YBZ00102025 一、药品基本情况 药品通用名称：玉女煎颗粒 主要成份：石膏、熟地黄、麦冬、知母等 剂型：颗粒剂 规格：每袋装 8g（相当于饮片 28.92g） 江苏康缘药业股份有限公司董事会 药品批准文号：国药准字 C20250006 1 药品生产企业：江苏康缘药业股份有限公司 二、药品研发及 ...